News

The protein Furin 1, produced by dopaminergic neurons — nerve cells that synthesize the neurotransmitter dopamine — triggers a harmful inflammatory molecular cascade in neighboring non-neuronal cells that contributes to the degradation of these neurons over time, a study in flies found. Because Furin 1 is controlled by LRRK2 — a major player…

Having a higher number of comorbidities is associated with postoperative confusion in Parkinson’s patients undergoing deep brain stimulation (DBS), according to a new study in Brazilian patients. The study, “Postoperative Confusion in Patients with Parkinson’s Disease Undergoing Deep Brain Stimulation of the Subthalamic Nucleus,” appeared in…

The Parkinson’s Foundation is bringing Allied Team Training for Parkinson’s (ATTP), its signature professional education program, to Iowa City, Iowa, on March 27-30. The program is intended to help medical professionals from diverse disciplines learn the best techniques in Parkinson’s care.  Using a dynamic team-based approach,…

ProMIS Neurosciences has identified several antibody candidates that specifically target the toxic forms of alpha-synuclein, a key component of Lewy bodies that underlie the development of Parkinson’s disease. In vitro (in the lab) studies have shown that ProMIS’s antibody candidates for Parkinson’s disease have a high specificity for toxic forms of…

Levodopa (L-DOPA) therapy is neuroprotective and prevents age-related iron accumulation in the substantia nigra, a brain region involved in Parkinson’s disease. The study with that finding, “L-DOPA modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson’s disease,” was published in…